Cerity Partners LLC Sells 12,246 Shares of Stryker Corporation $SYK

Cerity Partners LLC lowered its position in shares of Stryker Corporation (NYSE:SYK) by 3.9% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 305,753 shares of the medical technology company’s stock after selling 12,246 shares during the quarter. Cerity Partners LLC’s holdings in Stryker were worth $107,464,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Godfrey Financial Associates Inc. bought a new position in shares of Stryker during the 4th quarter worth approximately $26,000. United Financial Planning Group LLC bought a new position in shares of Stryker during the 3rd quarter worth approximately $27,000. CGC Financial Services LLC bought a new position in shares of Stryker during the 4th quarter worth approximately $29,000. Strive Asset Management LLC bought a new position in shares of Stryker during the 3rd quarter worth approximately $30,000. Finally, ANTIPODES PARTNERS Ltd bought a new position in shares of Stryker during the 3rd quarter worth approximately $34,000. Institutional investors own 77.09% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Sanford C. Bernstein set a $410.00 target price on shares of Stryker in a research report on Friday, May 1st. Barclays lowered their price target on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a report on Monday, May 4th. William Blair reaffirmed an “outperform” rating on shares of Stryker in a report on Thursday, March 5th. Robert W. Baird set a $385.00 price target on shares of Stryker in a report on Friday, May 1st. Finally, Truist Financial reaffirmed a “hold” rating and issued a $330.00 price target (down from $380.00) on shares of Stryker in a report on Monday, May 4th. Sixteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $395.33.

Stryker Price Performance

Shares of NYSE SYK opened at $314.41 on Wednesday. The stock has a market cap of $120.53 billion, a PE ratio of 36.39, a price-to-earnings-growth ratio of 1.90 and a beta of 0.78. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $404.87. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The stock has a fifty day moving average of $317.55 and a 200-day moving average of $345.01.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). The company had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. Stryker’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter last year, the firm posted $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities research analysts anticipate that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s payout ratio is 40.74%.

Insider Activity

In other news, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. The trade was a 30.04% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP M Kathryn Fink sold 5,220 shares of the business’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the transaction, the vice president owned 13,137 shares of the company’s stock, valued at $3,728,937.45. This trade represents a 28.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 323,264 shares of company stock worth $100,659,489 in the last three months. Corporate insiders own 4.60% of the company’s stock.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.